December 19, 2002 (download PDF)
Cypress Bioscience, Inc. Announces that Milnacipran is Effective in Animal Model of Fibromyalgia

December 17, 2002 (download PDF)
Cypress Bioscience, Inc. Milnacipran is Only Compound Shown to Preferentially Block Norepinephrine Uptake in In Vitro Model

December 10, 2002 (download PDF)
Cypress Bioscience, Inc.’s Milnacipran Significantly Improves Pain and Fatigue in Fibromyalgia Syndrome Patients

November 13, 2002 (download PDF)
Cypress Bioscience, Inc. Announces Third Quarter 2002 Results

November 11, 2002 (download PDF)
Cypress Bioscience, Inc. Drug Milnacipran Effective Analgesic for Visceral Pain in Animal Model

November 8, 2002 (download PDF)
Cypress Bioscience Inc. Drug Milnacipran Shown to Affect Multiple Pain Pathways

November 6, 2002 (download PDF)
Cypress Bioscience, Inc. Drug Milnacipran Effective in Antidepressant Animal Model

October 28, 2002 (download PDF)
Milnacipran Effective Analgesic in an Animal Model to Assess Analgesic Efficacy in Persistent Pain

October 7, 2002 (download PDF)
Milnacipran Pharmacology and Development Program Presented at National Fibromyalgia Research Association Conference

September 10, 2002 (download PDF)
Cypress Bioscience, Inc. Completes Enrollment of Phase II Milnacipran Clinical Trial Results Expected in Early 2003

September 5, 2002 (download PDF)
Cypress Bioscience, Inc. Establishes Collaboration with Collegium Pharmaceutical Inc. to Develop Second Generation Milnacipran

August 22, 2002 (download PDF)
Cypress Bioscience Inc. Launches Program to Evaluate Efficacy of Milnacipran in Depressed Mood Associated with Chronic Pain Conditions

August 21, 2002 (download PDF)
Improved System for Monitoring Pain Presented by Cypress Bioscience Inc. at World Congress on Pain Meeting

August 20, 2002 (download PDF)
Milnacipran Outperforms SNRI in an Animal Model to Assess Analgesic Efficacy in Chronic Pain

August 15, 2002 (download PDF)
Cypress Bioscience, Inc. Announces Second Quarter 2002 Results

July 9, 2002 (download PDF)
Cypress Bioscience, Inc. Comprehensive Review of the Neuropharmacology of Centrally-Acting Analgesic Medications in Fibromyalgia Syndrome Featured in Rheumatic Disease Clinics of North America

June 18, 2002 (download PDF)
Cypress Bioscience, Inc. Featured in invivodata Webconference

June 14, 2002 (download PDF)
Cypress Bioscience Featured in Fibromyalgia Aware Magazine

May 15, 2002 (download PDF)
Cypress Bioscience Announces First Quarter 2002 Results

April 8, 2002 (download PDF)
Cypress Bioscience, Inc. Meets NASDAQ Listing Requirements Resumes Normal Trading Under Symbol CYPB

April 2, 2002 (download PDF)
Auditors Withdraw "Going Concern Opinion"

April 1, 2002 (download PDF)
Cypress Bioscience, Inc. Closes $17 Million Financing

March 26, 2002 (download PDF)
Cypress Bioscience, Inc. Receives Stockholder Approval to Complete a $17 Million Private Placement

March 11, 2002 (download PDF)
Cypress Bioscience Announces Fourth Quarter and Fiscal Year End 2001 Results

March 7, 2002 (download PDF)
Nasdaq Agrees to Extend Cypress Bioscience, Inc. Listing on The Nasdaq SmallCap Market

February 25, 2002 (download PDF)
Cypress Bioscience Launches Phase II Program for Milnacipran in the Treatment of Fibromyalgia Syndrome

February 21, 2002 (download PDF)
Cypress Bioscience, Inc. Enters Into Agreements for Private Placement of $17 Million

February 14, 2002 (download PDF)
Cypress’ Comprehensive Review of the Psychopharmacology of Fibromyalgia Syndrome Featured in Psychopharmacology Bulletin

February 8, 2002 (download PDF)
Cypress Bioscience Names Sabrina Martucci Johnson Interim Chief Financial Officer

January 29, 2002 (download PDF)
Cypress Bioscience Advances FMS Initiative with the Launch of The Fibromyalgia Resource Center and On-line Patient Registry

January 24, 2002 (download PDF)
Cypress Bioscience receives Nasdaq delisting notice

January 7, 2002 (download PDF)
Cypress Bioscience to Begin Phase II Clinical Trial To Treat Fibromyalgia Syndromebromyalgia Syndrome